Acurx Pharmaceuticals, Inc. (ACXP)

NASDAQ: ACXP · IEX Real-Time Price · USD
0.09 (3.69%)
At close: May 27, 2022 3:56 PM
-0.40 (-15.42%)
After-hours:May 27, 2022 7:30 PM EDT

Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.

The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae.

Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc.
CountryUnited States
IPO DateJun 25, 2021
SectorHealth Care

Contact Details

259 Liberty Avenue
Staten Island, NY 10305
United States

Stock Details

Ticker SymbolACXP
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$6.00
CIK Code1736243

Key Executives

Robert J. DeLucciaCo-Founder and Executive Chairman
David P. Luci CPA, CPA, Esq., J.D.Corporate Secretary, Co-Founder, President, Chief Executive Officer and Director
Robert G. Shawah CPACo-Founder and Chief Financial Officer

Latest SEC Filings

May 11, 20228-KCurrent report
May 10, 202210-QQuarterly report [Sections 13 or 15(d)]
Apr 25, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2022DEF 14AOther definitive proxy statements
Mar 17, 20228-KCurrent report
Mar 16, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 16, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Nov 24, 20214Statement of changes in beneficial ownership of securities
Nov 22, 20214Statement of changes in beneficial ownership of securities
Nov 22, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings